ITHACA, New York, Aug. 26 -- Cornell University posted the following news:

* * *

Bioengineered bacteria could lead to therapeutic antibody drugs

*

A Cornell-led collaboration has devised a potentially low-cost method for producing antibodies for therapeutic treatments. They've bioengineered bacteria with an overlooked enzyme that can attach complex sugars, known as glycans, to monoclonal antibodies (mAbs) to boost their immune defenses.

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your Affiliation	Government Newspaper / Media Business Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions or comments:

Submit Form Click here for more information about our products